OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Doub...
OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
About this item
Full title
Author / Creator
Biller, Beverly MK , Newell-Price, John , Fleseriu, Maria , Bertagna, Xavier , Findling, James , Shimatsu, Akira , Lee, Eun Jig , Gu, Feng , Auchus, Richard , Leelawattana, Rattana , Lacroix, André , Kim, Jung Hee , Laplanche, Audrey , O'Connell, Paul , Tauchmanova, Libuse , Pedroncelli, Alberto and Pivonello, Rosario
Publisher
Washington, DC: Endocrine Society
Journal title
Language
English
Formats
Publication information
Publisher
Washington, DC: Endocrine Society
Subjects
More information
Scope and Contents
Contents
Background:
In a Phase II study, osilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD (Fleseriu M
et al. Pituitary
2016;19:138-48). We report the efficacy and safety of osilodrostat in a large CD patient population in the first randomized withdrawal Phase III study in...
Alternative Titles
Full title
OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6555000
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6555000
Other Identifiers
ISSN
2472-1972
E-ISSN
2472-1972
DOI
10.1210/js.2019-OR16-2
